FDA, CMS Scramble to Avoid Regulatory Logjam as States Test AI in Clinical Settings
OVERVIEWFederal regulators—the FDA and CMS—are working behind the scenes to prevent a regulatory conflict as states like Utah launch AI healthcare sandboxes enabling autonomous clinical decision-making (prescribing, drug management) before federal authorization pathways are complete. The regulatory tension centers on jurisdiction: FDA claims authority over AI medical devices, CMS controls Medicare/Medicaid coverage and payment, and states are advancing their own clinical testing frameworks. Without coordination, health systems face conflicting requirements and unclear liability assignments. Officials are attempting to establish informal guidelines and expedited review pathways to align state sandbox programs with federal oversight, but the underlying structural problem persists: no unified governance framework for adaptive AI systems that operate across state lines or receive federal payment. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.